Compare EVTC & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTC | KOD |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.3B |
| IPO Year | 2013 | 2018 |
| Metric | EVTC | KOD |
|---|---|---|
| Price | $27.79 | $32.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $35.80 | $35.43 |
| AVG Volume (30 Days) | 341.8K | ★ 557.3K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ 27.17 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $453,869,000.00 | N/A |
| Revenue This Year | $12.68 | N/A |
| Revenue Next Year | $6.86 | N/A |
| P/E Ratio | $60.04 | ★ N/A |
| Revenue Growth | ★ 11.48 | N/A |
| 52 Week Low | $21.81 | $9.80 |
| 52 Week High | $34.77 | $47.84 |
| Indicator | EVTC | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 37.14 | 28.41 |
| Support Level | $27.64 | $29.21 |
| Resistance Level | $30.40 | $45.23 |
| Average True Range (ATR) | 0.93 | 1.52 |
| MACD | -0.20 | -0.26 |
| Stochastic Oscillator | 4.44 | 8.50 |
Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions. Latin America Payments and Solutions segment derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.